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Design of protein-protein interaction inhibitors based on protein
epitope mimetics
Abstract
On the scaffold: Grafting protein epitopes onto conformationally designed scaffolds represents a very
promising approach to protein ligand design, with potential applications in many areas of chemical
biology and molecular medicine. The highlighted article describes the design and anticancer activity of
novel p53/MDM2 inhibitors built upon a scorpion toxin scaffold. Other approaches to protein epitope
mimetics are also briefly discussed.
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How can you design synthetic molecules to inhibit protein-protein interactions (PPIs)? What 
mechanistic principles can you use as an aid in inhibitor design? Unfortunately, the 
underlying mechanisms of protein-protein, or more generally protein-ligand recognition are 
still not very well understood. The basic physico-chemical properties of proteins together 
with the special solvent they are dissolved in (water), cannot yet be described accurately 
enough to allow rational de novo ligand design. The situation is not quite so bad for the case 
of enzymes, where mechanism-based approaches to inhibitor design are well established. 
These exploit knowledge of substrate and transition state structures, and the fact that enzyme 
active sites are typically found in deep pockets, which have evolved under intense selection 
pressure in Nature to bind reaction transition states with very high affinity (typically Ka = 
1016±4 M-1)[1]. Although we may not fully understand the origins of enzymic catalysis, even a 
poor transition state mimic might still bind and inhibit an enzyme in the nanomolar range. In 
comparison, PPIs have typically evolved in vivo to affinities only in the range Ka = 107±3 M-1. 
Protein-protein interfaces also tend to be relatively flat and rather large (700-1500 Å2 per 
protein)[2], and the surfaces of proteins often display complex dynamical behavior[3], all of 
which greatly complicates ligand design[4]. Neverthless, the practical importance of being 
able to design protein ligands and PPI inhibitors is enormous. Much of biology and medical 
research today is concerned with reducing complex biological processes to sets of protein-
protein, or more generally, protein-ligand interactions. Unfortunately, the experience of many 
pharmaceutical companies is that PPIs are a very difficult family of targets to hit using 
traditional small organic drug-like molecules[4-7]. 
 The report by Chong Li et al., in the J. Am. Chem. Soc. (2008, 130, 13546) is 
therefore of great interest, because it illustrates one successful approach to PPI inhibitors, 
based on the design of protein epitope mimetics[8]. Protein epitope mimetics can be viewed as 
relatively small synthetic molecules (about 1-2 kDa) that mimic the surface patches on folded 
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proteins involved in receptor binding. The mimetics should provide a well-defined 
(conformationally constrained) structural scaffold upon which the groups important for 
molecular recognition can be optimally displayed for interaction with the receptor. The 
synthetic origin of the mimetics is important, because then a myriad of synthetic methods can 
be used to ring the changes needed to optimize chemical, biological (and perhaps also other 
drug-like) properties. Apart from high affinity and specificity for the target receptor, another 
very important property required to inhibit intracellular PPIs, is cell membrane permeability. 
This issue was also addressed successfully in the work reported by Chong Li et al. 
 In a field as challenging as this, it is a good idea presently not to start your design 
efforts with the structurally most complex PPIs. The example studied by Chong Li et al. 
involves the interaction of a single short helical segment of the tumor suppressor protein p53 
with two regulators of p53 activity, called "mouse double minute 2" (MDM2) and MDMX[9, 
10]. The oncoproteins MDM2 and MDMX both negatively regulate the activity of p53 by 
binding to the same short helical epitope, with the sequence F19S20D21L22W23K24L25L26, 
which is located near the N-terminus of p53[11, 12]. Inhibitors of these PPIs have attracted 
great interest recently as anticancer agents[13, 14]. The N-terminal segment of p53 is at best 
loosely folded in solution and only becomes fully helical upon binding to MDM2 or 
MDMX[15-17]. In a helical conformation, however, the amino acids every 3/4 residues along 
the sequence align on the same face of the helix. In this case, it is the residues shown above 
in bold (F19, W23, L26) whose side chains can then dock into relatively hydrophobic pockets 
on the surface of MDM2 and MDMX (see Figure). These side chains are also energetically 
important for the affinity and selectivity of the interactions between p53 and MDM2 and 
MDMX. 
 By way of digression, it is interesting to note here that many PPIs are known, in 
which short helical epitopes dock with complementary binding sites on a receptor protein. 
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For example, the transactivation domains of many transcription factors contain short helical 
segments (so-called LXXLL motifs) that interact with other components of the transcriptional 
machinery[18]. So targeting this type of PPI with selective inhibitors could be used to inhibit a 
variety of biological processes, some with interesting applications in drug discovery. 
 Returning to the p53-MDM2/X story, the target for epitope mimetic design in this 
case was the helical segment of p53 encompassing residues 19-26. The aim was to transfer 
the energetically important groups (the side chains of F19, L22, W23 and L26 in p53) onto a 
relatively rigid synthetic scaffold, in a way that preserves binding affinity to the protein 
targets. Having a relatively rigid synthetic scaffold is a major advantage. This allows 
inhibitor optimization (affinity, specificity, stability, cell permeability, toxicity) using clear 
structure-activity relationships, and in a way that is often not possible in a linear flexible 
peptide molecule. The choice of scaffold then becomes a key parameter in epitope mimetic 
design. 
 Chong Li et al. chose for mimetic design a small, naturally occurring, highly cross-
linked peptide scaffold, belonging to the family of short-chain K+ channel toxins isolated 
from scorpion venom, called BmBKTx1[19]. Both X-ray and NMR solution structures are 
available (PDB files 1Q2K and 1R1G) for this 31-residue peptide[20, 21], which can be 
efficiently synthesized and oxidatively folded in vitro. This scaffold comprises a 3-turn N-
terminal α-helix, cross-linked by three disulfide bridges to a 14-residue ß-hairpin (see 
Figure). Both the α-helical segment and the ß-hairpin in BmBKTx1 provide 
conformationally stable segments onto which foreign epitopes can be grafted.  
 The utility of this scorpion α/ββ toxin fold for epitope mimetic design has been 
recognized for some time[19]. For example, the ß-hairpin motif in the toxin has been exploited 
to generate mimics of an epitope on the cellular receptor CD4[22-24], which binds to the HIV-1 
glycoprotein gp120. HIV-1 viral entry is initiated by the binding of gp120 to CD4 on host 
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cells. Crystallographic studies have shown that the key epitope on CD4, used for binding to 
gp120, is based largely on a surface ß-hairpin loop[25]. Transplanting this hairpin epitope from 
CD4 onto the scorpion toxin scaffold afforded, after optimization, mimetics that bind tightly 
to gp120 and inhibit HIV-1 entry to cells (see Figure)[22-24]. 
 In the work of Chong Li et al., the focus is on the α-helical segment of the scorpion 
toxin scaffold. The residues S6, R9, V10 and V13 in BmBKTx1 were replaced with the 
topologically equivalent residues from p53 (F19, L22, W23 and L26), and four terminal 
residues (A1, A2, and Y30, K31) were deleted, so giving a 27-residue peptide called stoppin-1. 
In this way, the key hydrophobic side chains required for interaction with both MDM2 and 
MDMX should be displayed in a helical array on the surface of the mimetic (see Figure). In 
addition to these hydrophobic contacts, however, two key hydrogen bonds should also be 
formed between the mimetic and the protein, namely, equivalent to those seen between the 
F19 (p53 numbering) backbone amide NH and the carbonyl side chain of Q72 in MDM2 (Q68 
in MDMX) and the indole NH of W23 and the L54 backbone carbonyl in MDM2 (M50 in 
MDMX). Stoppin-1 was studied in solution by CD spectroscopy, which supported the 
presumed structure. Then in direct binding assays, it was shown that stoppin-1 binds to both 
MDM2 and MDMX, with Kd values of 790 nM and 994 nM, respectively. For the linear p53 
peptide p53res.15-29 the Kd values were 123 nM and 279 nM, respectively. By contrast, the 
native wild-type toxin BmBKTx1 showed no affinity to either MDM2 or MDMX. 
 A further challenge was to engineer the mimetic to allow its uptake by cancer cells. 
At present there is growing interest in understanding how to design cell-permeable peptide-
like molecules, for example, through the N-methylation of peptide bonds in backbone cyclic 
peptides[26-28]. The N-methylation of peptide NH groups appears to aid transfer of such 
molecules through a lipophilic membrane environment, and so to facilitate their cell uptake, 
when these NHs are normally solvent exposed and able to hydrogen-bond to bulk solvent 
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water molecules. The approach taken by Chong Li et al., however, was different. They 
exploited the observation that some naturally occurring peptides containing multiple, closely 
spaced, cationic residues (called protein transduction domains, or simply, cell penetrating 
peptides)[29] are efficiently taken up across cell membranes. The mechanism(s) of cell uptake 
of cationic peptides is(are) still the subject of much scrutiny. The stoppin-1 mimetic was re-
engineered, by replacing 5 residues near the C-terminus (which are non-essential for binding 
to MDM2/X) with arginines, to create a cluster of 8 cationic residues projecting from the C-
terminal ß-hairpin motif. The resulting mimetic, stoppin-2, was shown to still bind to MDM2 
(Kd 493 nM). Next the ability of stoppin-2 to induce killing of cancer cells was studied. 
Stoppin-2 was shown to reduce viability of a p53+ cancer cell-line, and when added daily was 
able to kill the cells quantitatively. A variety of control experiments were performed to 
strengthen the conclusion that stoppin-2 kills tumor cells in a p53-dependent manner. 
 Given the widespread occurrence of α-helical epitopes in many PPIs, it is not 
surprising that many groups have reported efforts to design to α-helix mimics[30, 31]. For 
example, another relatively small folded peptide that has been used for engineering 
experiments is the avian pancreatic polypeptide (aPP)[32]. aPP contains 5-turns of α-helix in 
its C-terminal half, linked to a 10-residue extended (ß-structure) N-terminal segment, which 
is back-folded onto the α-helix. The p53 epitope has also been successfully grafted onto this 
aPP scaffold, to create miniprotein inhibitors of the p53-MDM2 interaction[33]. The cyclotides 
and conotoxins represent two other families of macrocyclic cross-linked peptides, each with 
great potential as scaffolds in protein ligand design[34-36]. Another approach to stabilize α-
helical conformations in linear peptides makes use of so-called "stapled helices". This 
involves covalently linking the side chains of residues lying one the same face of the helix (i 
and i+4) through amide, disulfide, or double (or similar) bonds[37, 38]. Stapled helical peptide 
mimetics of p53 have been reported that bind to MDM2 and reactivate the p53 tumor 
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suppressor pathway[39]. Another strategy for helix mimicry reported recently involves the 
design of bi and tri-aryl systems[30, 40, 41]. Due to restricted rotation in biaryl systems, 
substituents can be appended to the aromatic groups in a way that allows close mimicry of 
side chain residues i, i+4 and i+7 in α-helices. In this way, for example, terphenyls were 
designed to mimic the key helical region of p53, and also inhibit the p53/MDM2 
interaction[41]. Finally, there have been several examples reported of the use of ß-hairpin 
templates to mimic α-helical epitopes[42-44]. These exploit the close positional relationship 
between side chains at positions i and i+2 in a ß-strand with those at positions i and i+4 in an 
α-helix. Hairpin mimetics were designed in this way to mimic the helical epitope in p53, and 
so inhibit the p53/HDM2 interaction[42, 43]. Additional examples of p53/MDM2 inhibitors, 
including others based on helix-forming ß-peptides, have been described recently in an 
excellent review[45]. 
 Protein epitope mimetic design is clearly a very promising strategy in the search for 
novel PPI inhibitors. The great importance and potential for exploitation in this area of 
molecular design are certainly very clear. 
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Figure. The scorpion toxin scaffold is shown center (based on the crystal structure 
1R1G.pdb)[21], with Ser6, Val10 and Val13 changed to Phe, Trp and Leu, respectively, to 
mimic the helical epitope in p53 shown left (based on the crystal structure 1YCR.pdb)[11]. The 
same toxin scaffold has also been used to mimic a ß-hairpin epitope in CD4. Shown right is 
the mimetic (called CD4M33) bound to gp120 (crystal structure 1YYL.pdb)[22]. 
